1-3 of 3
Howard Burris, III
Close
Sort by
Journal Articles

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).

A. Keith Stewart, MB, ChB, Dan Sullivan, MD, Sagar Lonial, MD, Ann F. Mohrbacher, MD, Gurkamal Chatta, MD, Chaim Shustik, MD, Howard Burris, III, Michael Karol, PhD, Peter Zannikos, PhD, Donna E. Reece, MD
Journal: Blood
Blood (2006) 108 (11): 3533.
https://doi.org/10.1182/blood.V108.11.3533.3533
Published: 2006
Journal Articles

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Azra Raza, MD, Natalie Callander, MD, Leonel Ochoa, MD, Lawrence Piro, MD, Peter Emanuel, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Howard Burris, III, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Curtain, MD, Richard Larson, MD, Shelby Young, RN, Gail L. Brown, MD
Journal: Blood
Blood (2005) 106 (11): 2520.
https://doi.org/10.1182/blood.V106.11.2520.2520
Published: 2005
Journal Articles

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Natalie Callander, MD, Jose L. Ochoa-Bayona, MD, Lawrence Piro, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Ira Oliff, MD, Howard Burris, III, MD, Anneliese Jameson, Kiran Patel, Gail L. Brown, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Emanuel, MD
Journal: Blood
Blood (2004) 104 (11): 1428.
https://doi.org/10.1182/blood.V104.11.1428.1428
Published: 2004